Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Department of Obstetrics and Gynecology, Faculty of Medicine

1 abstract

Abstract
Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial: Mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in older patients with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression.
Org: Istituto Europeo Oncologia, Community Health Network, Inc, Wielkopolskie Centrum Onkologii, Department of Obstetrics and Gynecology, Faculty of Medicine,